Erratum: A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the b3 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladdera (Urology (2013) 82 (313-320))

Urology

Volumn 82, Issue 6, 2013, Pages 1457-

  Herschorn, Sender ^a   Barkin, Jack ^a   Castro Diaz, David ^a   Frankel, Jeffrey M ^a   Espuna Pons, Montserrat ^a   Gousse, Angelo E ^a   Stolzel, Matthias ^a   Martin, Nancy ^a   Gunther, Adrie ^a   Van Kerrebroeck, Philip ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ERRATUM; ERROR; PRIORITY JOURNAL;

EID: 84888645969     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2013.08.001     Document Type: Erratum

References (0)